Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.

Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, Picci P, Cambioli S, Donati D, Cevolani L, De Paolis M, Gambarotti M, Ferrari S.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):215-223. doi: 10.1007/s00259-016-3509-z. Epub 2016 Sep 20.

2.

Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.

Denecke T, Hundsdörfer P, Misch D, Steffen IG, Schönberger S, Furth C, Plotkin M, Ruf J, Hautzel H, Stöver B, Kluge R, Bierbach U, Otto S, Beck JF, Franzius C, Henze G, Amthauer H.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1842-53. doi: 10.1007/s00259-010-1484-3. Epub 2010 May 27.

PMID:
20505933
3.

Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.

Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF.

Cancer. 2002 Jun 15;94(12):3277-84. Erratum in: Cancer. 2003 Jun 195;97(12):3130.

4.

[18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.

Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU 3rd, Eary JF.

J Clin Oncol. 2005 Dec 1;23(34):8828-34.

PMID:
16314643
5.

Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.

Li YJ, Dai YL, Cheng YS, Zhang WB, Tu CQ.

Eur J Surg Oncol. 2016 Aug;42(8):1103-14. doi: 10.1016/j.ejso.2016.04.056. Epub 2016 May 3. Review.

PMID:
27189833
6.

[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.

Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF.

Cancer. 2009 Aug 1;115(15):3519-25. doi: 10.1002/cncr.24421.

7.

Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.

Qin Z, Tang Y, Wang H, Cai W, Fu H, Li J, Ma C.

J Pediatr Hematol Oncol. 2015 Jul;37(5):396-401. doi: 10.1097/MPH.0000000000000323.

PMID:
25749587
8.

18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

Salem U, Amini B, Chuang HH, Daw NC, Wei W, Haygood TM, Madewell JE, Costelloe CM.

J Cancer. 2017 Aug 25;8(15):2892-2898. doi: 10.7150/jca.20077. eCollection 2017.

9.

Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.

Byun BH, Kim SH, Lim SM, Lim I, Kong CB, Song WS, Cho WH, Jeon DG, Lee SY, Koh JS, Chung SK.

Eur Radiol. 2015 Jul;25(7):2015-24. doi: 10.1007/s00330-015-3609-3. Epub 2015 Feb 14.

PMID:
25680716
10.

Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.

Bajpai J, Kumar R, Sreenivas V, Sharma MC, Khan SA, Rastogi S, Malhotra A, Gamnagatti S, Kumar R, Safaya R, Bakhshi S.

J Pediatr Hematol Oncol. 2011 Oct;33(7):e271-8. doi: 10.1097/MPH.0b013e31820ff78e.

PMID:
22193290
11.

Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.

Ye Z, Zhu J, Tian M, Zhang H, Zhan H, Zhao C, Yang D, Li W, Lin N.

Ann Nucl Med. 2008 Jul;22(6):475-80. doi: 10.1007/s12149-008-0147-y. Epub 2008 Aug 1.

PMID:
18670853
12.

Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.

Raciborska A, Bilska K, Drabko K, Michalak E, Chaber R, Pogorzała M, Połczyńska K, Sobol G, Wieczorek M, Muszyńska-Rosłan K, Rychlowska-Pruszyńska M, Rodriguez-Galindo C, Dziuk M.

Clin Transl Oncol. 2016 Feb;18(2):189-95. doi: 10.1007/s12094-015-1351-6. Epub 2015 Aug 7.

PMID:
26250765
13.

F-18-FDG PET-CT in children and young adults with Ewing sarcoma diagnosed in Norway during 2005-2012: a national population-based study.

Johnsen B, Boye K, Rosendahl K, Biermann M, Trovik C, Aukland SM.

Clin Physiol Funct Imaging. 2016 Nov;36(6):441-446. doi: 10.1111/cpf.12247. Epub 2015 Jun 3.

PMID:
26039107
14.

Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience.

Kim DH, Kim SY, Lee HJ, Song BS, Kim DH, Cho JB, Lim JS, Lee JA.

Cancer Res Treat. 2011 Sep;43(3):170-5. doi: 10.4143/crt.2011.43.3.170. Epub 2011 Sep 30.

15.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782
16.

Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.

Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, Jeon DG, Koh JS, Lee SY, Lim SM.

J Nucl Med. 2013 Jul;54(7):1053-9. doi: 10.2967/jnumed.112.115964. Epub 2013 May 13.

17.
18.

Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy?

Song H, Jiao Y, Wei W, Ren X, Shen C, Qiu Z, Yang Q, Wang Q, Luo QY.

Eur Radiol. 2019 Jul;29(7):3945-3954. doi: 10.1007/s00330-019-06074-2. Epub 2019 Mar 11.

PMID:
30859285
19.

¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.

Kong CB, Byun BH, Lim I, Choi CW, Lim SM, Song WS, Cho WH, Jeon DG, Koh JS, Yoo JY, Lee SY.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):728-36. doi: 10.1007/s00259-013-2344-8. Epub 2013 Jan 30.

PMID:
23361860
20.

18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.

Hongtao L, Hui Z, Bingshun W, Xiaojin W, Zhiyu W, Shuier Z, Aina H, Yuanjue S, Daliu M, Zan S, Yang Y.

Surg Oncol. 2012 Dec;21(4):e165-70. doi: 10.1016/j.suronc.2012.07.002. Epub 2012 Aug 11. Review.

PMID:
22884956

Supplemental Content

Support Center